Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Autor: Kiss OC; Helmholtz Zentrum Dresden Rossendorf, Dresden, Germany. o.kiss@hzdr.de., Scott PJH; University of Michigan, Ann Arbor, MI, USA., Behe M; Paul Scherrer Institute, Villigen, Switzerland., Penuelas I; University Clinic of Navarra, Pamplona, Spain., Passchier J; Invicro, Imperial College London, London, UK., Rey A; Universidad de la Rebublica, Montevideo, Uruguay., Patt M; University of Leipzig, Leipzig, Germany., Aime S; University of Torino, Turin, Italy., Jalilian A; IAEA, Vienna, Austria., Laverman P; Radboud University Medical Center, Nijmegen, The Netherlands., Cheng Z; Shanghai Institute of Materia Medica, Shanghai, China., Chauvet AF; Inserm, Nantes, France., Engle J; University of Wisconsin, Madison, WI, USA., Cleeren F; Katholieke Universiteit, Leuven, Belgium., Zhu H; Peking University Cancer Hospital, Beijing, China., Vercouillie J; University of Tours, Tours, France., van Dam M; UCLA, Los Angeles, USA., Zhang MR; NIRS, Chiba, Japan., Perk L; Radboud University Medical Center, Nijmegen, The Netherlands., Guillet B; CERIMED, Marseille, France., Alves F; University of Coimbra, Coimbra, Portugal.
Jazyk: angličtina
Zdroj: EJNMMI radiopharmacy and chemistry [EJNMMI Radiopharm Chem] 2023 Mar 23; Vol. 8 (1), pp. 6. Date of Electronic Publication: 2023 Mar 23.
DOI: 10.1186/s41181-023-00192-5
Abstrakt: Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development.
Main Body: This selection of highlights provides commentary on 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals.
Conclusion: Trends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field, and include new PET-labelling methods for 11 C and 18 F, the importance of choosing the proper chelator for a given radioactive metal ion, implications of total body PET on use of radiopharmaceuticals, legislation issues and radionuclide therapy including the emerging role of 161 Tb.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje